Идёт
Фаза III
Беларусь
ИНЕБИЛИЗУМАБ · Viela Bio Inc./ Horizon Therapeutics, США/Horizon Therapeutics Ireland DAC (a wholly owned subsidiary of Amgen Inc.)
A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study With Open-label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults With Myasthenia Gravis